This was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government
A delegation of British pharmaceutical and biomed companies and organisations, headed by senior officials, will arrive in Israel to participate in the international BioMed conference (ATIA- ILSI) that will take place next week, 10-12 June 2013 in Tel Aviv. The delegation is made up of 20 members and is organised by the British Embassy in Israel, the UK Israel Tech Hub and UK Trade & Investment (UKTI).
Among the members who will be attending the event are representatives of the NHS- the British health services, NIHR- the British institute for Health Research, NICE- the National Institute for Excellence in Health, NOCRI- the NIHR Office for Clinical Research Infrastructure.
The British Embassy will display in pavilions #29-32. On Monday10 June, HE Matthew Gould, British Ambassador to Israel, together with Mr. Alistair Burt, MP, the Foreign Office minister, will honour the event with his presence.
The members of the delegation will hold a series of meetings with Israeli firms in search of cooperative ventures in development and the use of the UK as a springboard to Europe and the world at large. “Professor William Rosenberg, Scientific Advisor to NOCRI commented: “Through highlighting the world class offerings of the UK’s clinical research infrastructure, NOCRI is determined to develop and strengthen genuine collaborative partnerships between the UK and Israeli life science industries. Streamlined access to the NIHR’s technologically-advanced R&D facilities and skilled clinical research workforce can provide Israel companies with the support and backing required to develop patient-focused health treatments.”
The British ambassador to Israel, Mr. Mathew Gould said: “The coupling of Israeli innovation and entrepreneurship with worldclass and experienced British industry will be of enormous benefit to Israel companies. They will benefit from access to government programs that support companies in their initial stages, from the option to commercialize technology and develop it together with international pharmaceutical companies working in Britain.”